A Randomized, Double-blind, Placebo-controlled, Phase II, Multicenter Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetics of Subcutaneous JS005 in Chinese Adults With Active Non-radiographic Axial Spondyloarthritis
Latest Information Update: 07 Feb 2024
At a glance
- Drugs JS 005 (Primary)
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
Most Recent Events
- 18 Feb 2022 New trial record